TrialNature medicine2026

Immunotherapy with a short-lived anti-PD-L1 antibody in Alzheimer's disease: a phase 1b, randomized, double-blind trial.

Tommaso Croese et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.